TXG - Latest News
10x Genomics, Inc. (TXG), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $7.07B. Beta to the broader market is 2.03.
The article list below shows the most recent TXG headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent TXG Headlines
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
zacks.com - Nov 12, 2026
TXG's Xenium platform is set to power a 500-patient breast cancer biomarker study, expanding its oncology research footprint and precision diagnostics
Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform
prnewswire.com - Nov 10, 2026
Study aims to identify biomarkers that could predict how patients with breast cancer respond to neoadjuvant therapy PLEASANTON, Calif. , Nov.
What Torex Gold Resources (TXG) Said on Its Q3 Earnings Call
marketbeat.com - Nov 9, 2026
Torex Gold Resources TSE: TXG reported a 37% quarter-over-quarter increase in production in the third quarter of 2026, as higher grades and improved g
10x Genomics $TXG Stock: Chicago Partners Investment Group LLC Lowers Position
defenseworld.net - Nov 8, 2026
Chicago Partners Investment Group LLC lowered its position in shares of 10x Genomics (NASDAQ: TXG) by 29. 3% in the undefined quarter, according to th
10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis
zacks.com - Nov 6, 2026
TXG launches Sentira Single Cell, a Claude-powered AI tool to simplify complex data analysis, accelerate research and unlock recurring revenue potenti
How News Affects TXG Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track TXG's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked TXG news questions
- What is the latest TXG news headline?
- The most recent TXG headline (Nov 12, 2026) is "10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the TXG news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What TXG news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual TXG options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.